After 20 Years of Advocacy, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Finally Become Law
Transplantation
.
2022 Jan 1;106(1):9-11.
doi: 10.1097/TP.0000000000003899.
Authors
Macey L Levan
1
2
,
David J Reich
3
4
,
Dorry L L Segev
1
5
Affiliations
1
Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD.
2
Department of Acute and Chronic Care, Johns Hopkins School of Nursing, Baltimore, MD.
3
Department of Surgery, Drexel University College of Medicine, Philadelphia, PA.
4
Tower Health Transplant Institute, West Reading, PA.
5
Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD.
PMID:
34342961
PMCID:
PMC8678179
DOI:
10.1097/TP.0000000000003899
No abstract available
Publication types
Research Support, N.I.H., Extramural
MeSH terms
Humans
Immunosuppressive Agents / adverse effects
Kidney Transplantation* / adverse effects
Medicare
United States
Substances
Immunosuppressive Agents
Grants and funding
K01 DK114388/DK/NIDDK NIH HHS/United States
K24 AI144954/AI/NIAID NIH HHS/United States